AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2530925
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (saline with 12 ml of 0.25% plain bupivacaine)
Trial: 28632487
Drug: Cytarabine plus
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cytarabine plus high-dose daunorubicin (AD)
Trial: 28632487
Drug: Cytarabine plus
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cytarabine plus high-dose daunorubicin (AD) in patients with FLT3 ITD mutation
Trial: 19796205
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with house dust mite extracts
Trial: 16500336
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E with conjugated equine estrogen (CEE) (0.625 mg)
Trial: 16500336
Drug: CEE (0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE (0.625 mg) plus medroxyprogesterone acetate (MPA) (2.5 mg)
Trial: 10955327
Drug: naproxen 500
RxNorm normalized name: naproxen 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naproxen 500 mg bid (n = 1,099)
Trial: 10955327
Drug: celecoxib 50
RxNorm normalized name: celecoxib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: celecoxib 50 mg bid (n = 690)
Trial: 10955327
Drug: celecoxib 100
RxNorm normalized name: celecoxib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: celecoxib 100 mg bid (n = 1,131)
Trial: 10955327
Drug: celecoxib 200
RxNorm normalized name: celecoxib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: celecoxib 200 mg bid (n = 1,125)
Trial: 10955327
Drug: celecoxib 400
RxNorm normalized name: celecoxib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: celecoxib 400 mg bid (n = 434)
Trial: 8968014
Drug: Low-dose chlorthalidone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose chlorthalidone (12.5-25.0 mg/d) with step-up to atenolol (25.0-50.0 mg/d) or reserpine (0.05-0.10 mg/d)
Trial: 1316075
Drug: Lomefloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lomefloxacin (400 mg once daily)
Trial: 29901417
Drug: Exercise +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise + supplement (ES) group
Trial: 29901417
Drug: Supplement (S)
RxNorm normalized name: S-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplement (S) group
Trial: 26335787
Drug: Standard antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antibiotics plus pidotimod (PDT)
Trial: 26335787
Drug: Standard antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antibiotics alone
Trial: 18496296
Drug: Perindopril 4
RxNorm normalized name: perindopril 4 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril 4 mg daily (n=27)
Trial: 18496296
Drug: Metoprolol 100
RxNorm normalized name: metoprolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 100 mg daily (n=28)
Trial: 16796157
Drug: Reduced-osmolarity ORS
RxNorm normalized name: Orserdu
DrugBank: Elacestrant (DB06374)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced-osmolarity ORS solution (245 mmol/L)
Trial: 16796157
Drug: Standard WHO-ORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard WHO-ORS solution (311 mmol/L)
Trial: 12657118
Drug: Interferon alpha-2b
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon alpha-2b plus radiation therapy
Trial: 11048902
Drug: Olanzapine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (5 to 25 mg orally once daily for 18 weeks)
Trial: 9072308
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg dolasetron
Trial: 9072308
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg dolasetron
Trial: 9070501
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of dolasetron
Trial: 29859385
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D (50,000 IU every 2 weeks) plus omega-3 fatty acid (2000 mg/day)
Trial: 24420547
Drug: 100,000 U
RxNorm normalized name: nystatin 100,000 UNT Oral Lozenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100,000 U oral vitamin D3 every 2 months
Trial: 8266016
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg sulglycotide three times daily (n = 50)
Trial: 27086046
Drug: Mental Incisal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mental Incisal Nerve Block (MINB) with 2 mL 2% lidocaine with 1:200,000 epinephrine and a mock IANB with 2 mL sterile saline
Trial: 27086046
Drug: Inferior Alveolar
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inferior Alveolar Nerve Block (IANB) with 2 mL 2% lidocaine
Trial: 27086046
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of MINB and IANB with 2 mL each of 2% lidocaine
Trial: 25065535
Drug: Brief motivational
RxNorm normalized name: ALCOHOL 300 mL in 375 mL TOPICAL LIQUID [Nelsons Clean Brier Tennessee Handwash]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief motivational interviewing and cognitive behavioural therapy (MI-CBT) intervention (up to 12 sessions over 4.5 months) with standard care
Trial: 25065535
Drug: Long motivational
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long motivational interviewing and cognitive behavioural therapy (MI-CBT) intervention (up to 24 sessions over 9 months) with standard care
Trial: 20163375
Drug: Renzapride 4
RxNorm normalized name: Renzapride
DrugBank: Renzapride (DB04917)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renzapride 4 mg daily
Trial: 17453011
Drug: Occupational therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational therapy (OT) program combined with neuromotor rehabilitation
Trial: 12186803
Drug: Abnormal renal
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abnormal renal function (creatinine clearance <70 mL/min) in the STE group
Trial: 12186803
Drug: Abnormal renal
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abnormal renal function (creatinine clearance <70 mL/min) in the NSE group
Trial: 7992239
Drug: Diet rich
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet rich in fish (250 g daily for six weeks)
Trial: 2538300
Drug: Isocaloric diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isocaloric diet rich in fibres (70 g/day)
Trial: 2538300
Drug: Isocaloric diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isocaloric diet enriched by guar (9 g of guar added to 30 g of natural fibres/day)
Trial: 29122523
Drug: 0.2 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 g/kg of a 20% SCIg solution (IgPro20) weekly
Trial: 29122523
Drug: 0.4 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 g/kg of a 20% SCIg solution (IgPro20) weekly
Trial: 29122523
Drug: Placebo (2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2% human albumin solution)
Trial: 29122523
Drug: 0.2 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 g/kg SCIg vs Placebo
Trial: 29122523
Drug: 0.4 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 g/kg SCIg vs Placebo
Trial: 29122523
Drug: 0.4 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 g/kg SCIg vs 0.2 g/kg SCIg
Trial: 27633186
Drug: Semaglutide (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semaglutide (0.5 mg or 1.0 mg)
Trial: 23153360
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard school uniforms without insecticide treatment)
Trial: 21142442
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy including lopinavir/ritonavir
Trial: 17484706
Drug: Lactobacillus rhamnosus
RxNorm normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus rhamnosus GG (LGG) in the form of commercially available yoghurt, 100 g daily for 4 weeks
Trial: 14764410
Drug: Selegiline (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selegiline (10 mg per os daily for 120 days)
Trial: 2344897
Drug: Quinidine (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinidine (1200 mg/die)
Trial: 2344897
Drug: Lidoflazine (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidoflazine (240 mg/die)
Trial: 29231159
Drug: Intra-articular lumbar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular lumbar facet-joint injections with steroids
Trial: 15125520
Drug: Daily topical
RxNorm normalized name: Clindagel 1 % Once-Daily Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily topical application of 1/3 diluted camphor oil with glycerol and 500 mg metronidazole orally for fifteen days
Trial: 11779901
Drug: Acetaminophen 650
RxNorm normalized name: acetaminophen 650 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 650 mg every 4 hours for 24 hours
Trial: 9640568
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (group A)
Trial: 8074628
Drug: Caffeine (CAF)
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine (CAF) 4 mg.kg‐1
Trial: 2561141
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg nifedipine twice a day
Trial: 2561141
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg enalapril once a day
Trial: 25970252
Drug: D-cycloserine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-cycloserine (50 mg) administered 1 hour before each of 5 exposure and response prevention tasks
Trial: 25970252
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered 1 hour before each of 5 exposure and response prevention tasks
Trial: 19125674
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of Helicobacter pylori infection
Trial: 28453838
Drug: Multivalent GI.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivalent GI.1 and GII.4c norovirus VLP vaccine candidate adjuvanted with alum and MPL
Trial: 26515660
Drug: Combined donepezil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined donepezil discontinuation groups
Trial: 18663402
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of ibandronate (ACE doses > or = 10.8 mg: 150 mg once monthly, 3 mg i.v. quarterly, 2 mg i.v. every 2 months)
Trial: 18663402
Drug: Lower doses
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower doses of ibandronate (ACE doses of 5.5 mg)
Trial: 18663402
Drug: ACE doses
RxNorm normalized name: Zodryl AC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE doses of 7.2‐12 mg
Trial: 10679645
Drug: Lanreotide 30
RxNorm normalized name: lanreotide 300 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanreotide 30 mg intramuscularly every 10 days for 1 month
Trial: 10679645
Drug: Octreotide 200
RxNorm normalized name: octreotide 200 mcg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide 200 microg subcutaneously twice or thrice daily for 1 month
Trial: 28493741
Drug: 0.45g/kg alcohol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.45g/kg alcohol dose in activational condition
Trial: 28493741
Drug: 0.65g/kg alcohol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.65g/kg alcohol dose in activational condition
Trial: 28493741
Drug: 0.45g/kg alcohol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.45g/kg alcohol dose in inhibitory condition
Trial: 28493741
Drug: 0.65g/kg alcohol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.65g/kg alcohol dose in inhibitory condition
Trial: 23283838
Drug: D-cycloserine (DCS)
RxNorm normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D-cycloserine (DCS) 250 mg
Trial: 19633577
Drug: Balsalazide 2.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balsalazide 2.25 g/day
Trial: 11421842
Drug: Bupivacaine 1
RxNorm normalized name: bupivacaine 132 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 1 ml kg(‐1)
Trial: 11421842
Drug: Bupivacaine 1
RxNorm normalized name: bupivacaine 132 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 1 ml kg(‐1) + Tramadol 1.5 mg kg(‐1)
Trial: 2695178
Drug: 10 Gy‐Co‐60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 Gy‐Co‐60 single dose of TBI plus 120 mg/kg of cyclophosphamide over 2 days (Group A)
Trial: 2695178
Drug: 12 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 Gy Co‐60 of TBI in 6 fractions (2/day) plus 120 mg/kg of cyclophosphamide over 3 days (Group B)
Trial: 38177
Drug: Azathioprine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azathioprine (2.5 mg/kg body weight)
Trial: 19855847
Drug: Engerix B
RxNorm normalized name: Engerix-B
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Engerix B hepatitis B vaccine
Trial: 17112442
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids (9 g)
Trial: 7921908
Drug: 75 g
RxNorm normalized name: Zosyn 3.375 GM Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 g of glucose in 300 ml of water (G trial)
Trial: 7921908
Drug: 300 ml
RxNorm normalized name: HYQVIA 30 GM / 300 ML Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 ml of sweetened water (P trial)
Trial: 3202370
Drug: Active sustained-release
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active sustained-release theophylline preparation
Trial: 3202370
Drug: Placebo sustained-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo sustained-release theophylline preparation
Trial: 31597020
Drug: Faster increment
RxNorm normalized name: diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Faster increment (30 ml/kg/day)
Trial: 31597020
Drug: Slower increment
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slower increment (18 ml/kg/day)
Trial: 25728587
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (infliximab and azathioprine)
Trial: 19660005
Drug: Rivaroxaban 20
RxNorm normalized name: rivaroxaban 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 20 mg single dose
Trial: 19660005
Drug: Rivaroxaban 20
RxNorm normalized name: rivaroxaban 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 20 mg multiple doses (twice daily for 6 days)
Trial: 19660005
Drug: Rivaroxaban (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (various doses: 2.5, 5, 10, 20, 40 mg single dose; 5, 10, 20, 30 mg multiple doses)
Trial: 11549430
Drug: Early hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early hormonal therapy with LHRH analogue plus radiotherapy (COMB)
Trial: 9820373
Drug: Folate supplementation
RxNorm normalized name: folate
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folate supplementation (5 mg/d for 6 months)
Trial: 8164029
Drug: Dexamethasone 10
RxNorm normalized name: dexamethasone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 10 mg i.v. plus ondansetron 8 mg i.v. prechemotherapy plus ondansetron 8 mg orally every 12 hours postchemotherapy for nine doses
Trial: 8164029
Drug: Dexamethasone 10
RxNorm normalized name: dexamethasone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 10 mg i.v. plus ondansetron 16 mg i.v. prechemotherapy plus placebo orally postchemotherapy
Trial: 8164029
Drug: Dexamethasone 10
RxNorm normalized name: dexamethasone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 10 mg i.v. plus ondansetron 8 mg prechemotherapy plus ondansetron 8 mg orally postchemotherapy for one dose followed by placebo orally every 12 hours for eight more doses
Trial: 2845011
Drug: Alternating chemotherapy
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternating chemotherapy (cyclophosphamide, Adriamycin, vincristine alternating with etoposide and cisplatin)
Trial: 31994254
Drug: Juul (59
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Juul (59 mg nicotine/ml)
Trial: 26497643
Drug: Mg-enriched hydroxyapatite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mg-enriched hydroxyapatite (Mg-e HA) grafted into the socket for 4 months
Trial: 26497643
Drug: Mg-enriched hydroxyapatite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mg-enriched hydroxyapatite (Mg-e HA) grafted into the socket for 12 months
Trial: 26497643
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of Mg-e HA at 4 months vs 12 months
Trial: 24943283
Drug: Good practice
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Good practice treatment intervention (6 hours contact over 24 weeks, group-based)
Trial: 8688256
Drug: fentanyl 4
RxNorm normalized name: fentanyl 400 MCG Buccal Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fentanyl 4 micrograms ml‐1 (group F)
Trial: 8688256
Drug: 0.05% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% bupivacaine combined with fentanyl 2 micrograms ml‐1 (group BF)
Trial: 8250364
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: 20 ml bolus of 0.25% bupivacaine followed by a continuous steady rate infusion (10 ml.h‐1)
Trial: 8250364
Drug: Group C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C: Normal saline administered in the same way as Group B
Trial: 3030861
Drug: DPTP vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPTP vaccine (2 doses)
Trial: 3030861
Drug: DPT and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPT and IPV (2 doses)
Trial: 3030861
Drug: DPT and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPT and OPV (2 doses)
Trial: 3030861
Drug: DPTP vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPTP vaccine (1 year follow-up)
Trial: 25367636
Drug: Stress management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stress management intervention combining individual cognitive behavioral therapy (CBT) with a brief workplace intervention (N=57)
Trial: 15309420
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose loading (75 g glucose in 300 mL water)
Trial: 12540321
Drug: Antacids and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacids and H2 blockers
Trial: 7659477
Drug: Lederle vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lederle vaccine
Trial: 7659477
Drug: MPHBL vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPHBL vaccine
Trial: 2679953
Drug: Silver sulphadiazine
RxNorm normalized name: Silver sulphadiazine
DrugBank: Silver sulfadiazine (DB05245)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silver sulphadiazine cream (SSD)
Trial: 175434
Drug: Metacycline treatment
RxNorm normalized name: Metacycline
DrugBank: Metacycline (DB00931)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metacycline treatment
Trial: 29766292
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g of extra virgin olive oil (EVOO)
Trial: 28618298
Drug: Online Behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online Behavioral Activation treatment
Trial: 28618298
Drug: No stressful
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No stressful life event during therapy
Trial: 25051124
Drug: CAF-5 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAF-5 (5 mg.kg‐1)
Trial: 25051124
Drug: CAF-3 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAF-3 (3 mg.kg‐1)
Trial: 25051124
Drug: CAF-1 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAF-1 (1 mg.kg‐1)